Minimum Laboratory Monitoring For Psychotropic Medications

ANTIPSYCHOTIC MEDICATIONS
GENERIC BRAND GENERIC BRAND
Aripiprazole Abilify, Abilify Olanzapine Zyprexa, Zyprexa Zydis
Maintena, Aristada
Asenapine Saphris Paliperidone Invega, Invega Sustenna, Invega Trinza
Brexpiprazole Rexulti Perphenazine Trilafon
Cariprazine Vraylar Pimozide Orap
Chlorpromazine Thorazine Quetiapine Seroquel, Seroquel XR
Clozapine Clozaril, Fazaclo Risperidone Risperdal, Risperdal Consta, Risperdal M Tabs
Fluphenazine, Fluphenazine D Prolixin, Prolixin D Thioridazine Mellaril
Haloperidol, Haloperidol D Haldol, Haldol D Thiothixene Navane
Iloperidone Fanapt Trifluoperazine Stelazine
Loxapine Loxitane Ziprasidone Geodon
Lurasidone Latuda

MONITORING ANTIPSYCHOTIC FREQUENCY OF MONITORING

AIMS (Abnormal Involuntary Movement Scale)
ABDOMINAL GIRTH (>18 years old)
WEIGHT & BODY MASS INDEX (BMI)
HEART RATE & BLOOD PRESSSURE
COMPREHENSIVE METABOLIC PANEL (CMP),
LIPIDS, FASTING GLUCOSE AND COMPLETE
BLOOD COUNT (CBC)
On initiation of any antipsychotic medication and at least every six months
thereafter, or more frequently as clinically indicated.
For individuals at least 18 years old, on initiation of any medication and at
least every six months thereafter, or more frequently as clinically indicated.
On initiation of any medication and at least every six months thereafter, or
more frequently as clinically indicated.
On initiation of any medication and at least every six months thereafter, or
more frequently as clinically indicated.
On initiation of any medication affecting this parameter and at least annually
thereafter or more frequently as clinically indicated.

CLOZAPINE MONITORING
MONITORING FREQUENCY OF MONITORING
White Blood Cell Count (WBC) w/ Absolute Neutrophil Weekly for 1st 6 months (if values within normal limits), then every 2 wks. for
Count (ANC) 6 months, then monthly (if values within normal limits)
Comprehensive Metabolic Panel (CMP) At least annually
Fasting Lipid Panel At least annually

LITHIUM MONITORING
MONITORING FREQUENCY OF MONITORING
Lithium Level Within one month of initiation of lithium or significant change in dose and at least every six months thereafter or
more frequently as clinically indicated.
Thyroid Function Within one month of initiation of lithium and at least annually thereafter or more frequently as clinically
indicated.
CBC w/ Platelet On initiation of any medication affecting this parameter and at least annually thereafter or more frequently as
Count clinically indicated.
CMP Renal function – within one month of initiation of lithium and at least annually thereafter or more frequently as
clinically indicated.

VALPROIC ACID MONITORING

MONITORING FREQUENCY OF MONITORING
Valproic Acid Level Within one month of initiation of valproic acid or divalproex or significant change in dose and at least annually
and CMP thereafter or more frequently as clinically indicated.
CBC with Platelet On initiation of any medication affecting this parameter and at least annually thereafter or more frequently as
Count clinically indicated.

CARBAMAZEPINE MONITORING
MONITORING FREQUENCY OF MONITORING
Carbamazepine Level, Within 1 month of initiation of carbamazepine or significant change in dose and at least annually thereafter or
CMP and TSH more frequently as clinically indicated.
CBC w/ Platelet Count On initiation of any medication affecting this parameter and at least annually thereafter or more frequently as
clinically indicated.

Updated: 7/2019